Document is current
Any future updates will be listed below
-
Authors
Candela, Maria Elena https://orcid.org/0000-0003-4775-163X
Addison, Melisande
Aird, Rhona https://orcid.org/0000-0002-1014-8063
Man, Tak-Yung
Cartwright, Jennifer A. https://orcid.org/0000-0003-1143-9011
Ashmore-Harris, Candice https://orcid.org/0000-0001-9270-8599
Kilpatrick, Alastair M.
Starkey Lewis, Philip J.
Drape, Anna
Barnett, Mark
Mitchell, Donna
McLean, Colin
McGowan, Neil
Turner, Marc
Dear, James W. https://orcid.org/0000-0002-8630-8625
Forbes, Stuart J. https://orcid.org/0000-0003-3715-2561
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/T044802/1, MR/T044802/1, MR/T044802/1, MR/T044802/1, MR/T044802/1, MR/T044802/1, MR/T044802/1)
Centre for Precision Cell Therapy for the Liver
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 10 January 2025
First Online: 22 January 2025
Competing interests
: S.J.F. and P.J.S.L. are founders of Resolution Therapeutics, which is developing a macrophage cell therapy product to treat patients at risk of liver decompensation; A.M.K. is a consultant to Resolution Therapeutics. The remaining authors declare no competing interests.
